Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, Alvegard TA, Brach Del Prever A, Tamburini A, Alberghini M, Gandola L, Mercuri M, Capanna R, Mapelli S, Prete A, Carli M, Picci P, Barbieri E, Bacci G, Smeland S. Ferrari S, et al. Among authors: smeland s. Ann Oncol. 2011 May;22(5):1221-1227. doi: 10.1093/annonc/mdq573. Epub 2010 Nov 8. Ann Oncol. 2011. PMID: 21059639 Free article. Clinical Trial.
Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235].
Budde A, Baust K, Weinhold L, Bernstein M, Bielack S, Dhooge C, Hjorth L, Janeway KA, Jenney M, Krailo MD, Marina N, Nagarajan R, Smeland S, Sydes MR, De Vos P, Whelan J, Wiener A, Calaminus G, Schmid M. Budde A, et al. Among authors: smeland s. Eur J Cancer. 2022 Dec;177:208-209. doi: 10.1016/j.ejca.2022.06.053. Epub 2022 Nov 5. Eur J Cancer. 2022. PMID: 36347760 Free PMC article. No abstract available.
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Saeter G. Smeland S, et al. Eur J Cancer. 2003 Mar;39(4):488-94. doi: 10.1016/s0959-8049(02)00747-5. Eur J Cancer. 2003. PMID: 12751380
The Scandinavian Sarcoma Group Register 1986-2001.
Bauer HC, Alvegård TA, Berlin O, Erlanson M, Kalén A, Lindholm P, Gustafson P, Smeland S, Trovik CS. Bauer HC, et al. Among authors: smeland s. Acta Orthop Scand Suppl. 2004 Apr;75(311):8-10. doi: 10.1080/00016470410001708260. Acta Orthop Scand Suppl. 2004. PMID: 15188659 No abstract available.
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G; Italian and Scandinavian Sarcoma Groups. Ferrari S, et al. Among authors: smeland s. J Clin Oncol. 2005 Dec 1;23(34):8845-52. doi: 10.1200/JCO.2004.00.5785. Epub 2005 Oct 24. J Clin Oncol. 2005. PMID: 16246977 Clinical Trial.
104 results